Travis Mickle
Chairman at KemPharm Denmark A/S
Net worth: 254 110 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Christal Mickle | F | 45 |
New River Pharmaceuticals, Inc.
 New River Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology New River Pharmaceuticals, Inc. develops pharmaceutical products. Its product candidates in clinical development are an amphetamine derivative (NDA filed) and an opioid derivative that they believe will provide alternatives to marketed drugs. The company was founded by Randal J. Kirk in 1996 and is headquartered in Radford, VA. | 22 years |
| R. Clifton | M | 51 | 9 years | |
| Tamara Favorito | F | 65 | 3 years | |
| Raymond la Duane Clifton | M | - |
KemPharm Denmark A/S
 KemPharm Denmark A/S Miscellaneous Commercial ServicesCommercial Services Part of Zevra Therapeutics, Inc., KemPharm Denmark A/S is a Danish company that engages in the development of novel treatments for central nervous system. The company is based in Copenhagen, Denmark. The company was founded in 2022. The CEO is Raymond la Duane Clifton. | - |
| Douglas Calder | M | 56 | 1 years | |
| Nichol Ochsner | M | - | 2 years | |
| Sven Guenther | M | 52 | 17 years | |
| Corey Watton | M | 54 | 1 years | |
| John Bode | M | 49 | 1 years | |
| Christopher Lauderback | M | - |
New River Pharmaceuticals, Inc.
New River Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology New River Pharmaceuticals, Inc. develops pharmaceutical products. Its product candidates in clinical development are an amphetamine derivative (NDA filed) and an opioid derivative that they believe will provide alternatives to marketed drugs. The company was founded by Randal J. Kirk in 1996 and is headquartered in Radford, VA. | 19 years |
| Wendy Dixon | M | 68 | 1 years | |
| Daniel Gallo | M | - | 1 years | |
| Robert Philibert | M | 63 |
University of Iowa
| 26 years |
| Rene A. Braeckman | M | - | 8 years | |
| Thomas Weitemeyer | M | - |
KemPharm Denmark A/S
KemPharm Denmark A/S Miscellaneous Commercial ServicesCommercial Services Part of Zevra Therapeutics, Inc., KemPharm Denmark A/S is a Danish company that engages in the development of novel treatments for central nervous system. The company is based in Copenhagen, Denmark. The company was founded in 2022. The CEO is Raymond la Duane Clifton. | - |
| Joshua Schafer | M | 53 | 1 years | |
| Timothy Sangiovanni | M | 40 | 7 years | |
| Abbi Maher | F | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Gordon K. Johnson | M | 72 | 7 years | |
| Richard Pascoe | M | 60 | 9 years | |
| Matthew Plooster | M | 42 | 12 years | |
| Krish S. Krishnan | M | 59 |
New River Pharmaceuticals, Inc.
New River Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology New River Pharmaceuticals, Inc. develops pharmaceutical products. Its product candidates in clinical development are an amphetamine derivative (NDA filed) and an opioid derivative that they believe will provide alternatives to marketed drugs. The company was founded by Randal J. Kirk in 1996 and is headquartered in Radford, VA. | 4 years |
| Todd Doorenbos | M | - | - | |
| Karlton Kleis | M | - | - | |
| Doug Weih | M | - |
University of Iowa
| 11 years |
| Yu Sun | M | - |
University of Iowa
| 4 years |
| Danny L. Thompson | M | 60 | 12 years | |
| Daniel Cohen | M | 65 | 2 years | |
| Christopher Posner | M | 54 | - | |
| Todd J. Johnson | M | - | - | |
| Joseph Saluri | M | 57 | 9 years | |
| Ross A. Junge | M | - |
Simpson College
University of Iowa
| 7 years |
| Nathan R. Hamler | M | - |
University of Iowa
| 6 years |
| David Tierney | M | 60 | - | |
| John Mickelson | M | - |
University of Iowa
| 8 years |
| Ryan Jordan | M | - |
University of Iowa
| 4 years |
| Vern A. Gebhart | M | - |
University of Iowa
| 2 years |
| Arindam Kar | M | - |
University of Iowa
| 4 years |
| Don Davidson | M | - |
University of Iowa
| 4 years |
| Dennis Dorman | M | - |
University of Iowa
| 4 years |
| Abby M. Stach | F | - |
University of Iowa
| 4 years |
| Matt Kennedy | M | - |
University of Iowa
| 4 years |
| Yi Gong Chen | M | 53 |
University of Iowa
| 4 years |
| Calista J. Mitchell | F | - |
University of Iowa
| 4 years |
| Troy Beachler | M | - |
University of Iowa
| 4 years |
| Andy Cullen | M | - |
Simpson College
| 4 years |
| Samantha Shows | F | - |
University of Iowa
| 5 years |
| Ryan Barton | M | - |
University of Iowa
| 4 years |
| Chi-wai Lee | M | 46 |
University of Iowa
| 4 years |
| Brian T. Asby | M | - |
University of Iowa
| 4 years |
| Brian Grogan | M | - |
University of Iowa
| 4 years |
| Timothy Millage | M | 43 |
University of Iowa
| 5 years |
| Michal Eynon-Lynch | F | - |
University of Iowa
| 4 years |
| Chris Freitag | M | - |
University of Iowa
| 4 years |
| Gregory Liebbe | M | - |
University of Iowa
| 4 years |
| Joshua B. Dolin | M | 49 |
University of Iowa
| 4 years |
| Doug Oest | M | - |
University of Iowa
| 4 years |
| Srinivas Nalamachu | M | - | - | |
| Jeffrey Gudin | M | 58 | - | |
| Matthew Stephen Szafranski | M | 47 |
University of Iowa
| 4 years |
| Kristin Dawn Singer | F | - |
University of Iowa
| 4 years |
| Aaron Uitenbroek | M | - |
University of Iowa
| 5 years |
| Dennis A. Gastineau | M | - |
University of Iowa
| 12 years |
| James Whittle | M | - |
University of Iowa
| 3 years |
| Roger Griggs | M | - |
New River Pharmaceuticals, Inc.
New River Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology New River Pharmaceuticals, Inc. develops pharmaceutical products. Its product candidates in clinical development are an amphetamine derivative (NDA filed) and an opioid derivative that they believe will provide alternatives to marketed drugs. The company was founded by Randal J. Kirk in 1996 and is headquartered in Radford, VA. | - |
| Hao Yu Shen | M | 54 |
University of Iowa
| 2 years |
| Bala Ragothaman | M | - |
University of Iowa
| 1 years |
| Rounak Singh Langhe | M | - |
University of Iowa
| 2 years |
| Richard Romano | M | - |
University of Iowa
| 3 years |
| Peter Masucci | M | - |
University of Iowa
| 4 years |
| Matt Reischl | M | - |
University of Iowa
| 2 years |
| Lee J. Wise | M | - |
University of Iowa
| 4 years |
| Kiran Rijhsinghani | M | - |
University of Iowa
| 4 years |
| Marco Minonne | M | - |
University of Iowa
| 4 years |
| Jeff Madden | M | - |
University of Iowa
| 4 years |
| Brian L. Machan | M | - |
University of Iowa
| 2 years |
| Eugene F. Wilcauskas | M | - |
New River Pharmaceuticals, Inc.
New River Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology New River Pharmaceuticals, Inc. develops pharmaceutical products. Its product candidates in clinical development are an amphetamine derivative (NDA filed) and an opioid derivative that they believe will provide alternatives to marketed drugs. The company was founded by Randal J. Kirk in 1996 and is headquartered in Radford, VA. | 5 years |
| John W. Colloton | M | 93 |
University of Iowa
| 7 years |
| Joel J. Schmidt | M | 61 |
University of Iowa
| 2 years |
| Melanie Creagan Dreher | M | - |
University of Iowa
| 9 years |
| Shane C. Larson | M | - |
University of Iowa
| 2 years |
| Jerry Israel | M | 81 |
Simpson College
| 5 years |
| Jake W. Nelson | M | - |
University of Iowa
| 4 years |
| Jonathan P. Fairchild | M | - |
University of Iowa
| 4 years |
| Heidi M. Furlong | F | - |
University of Iowa
| 4 years |
| Kathleen H. Holt | M | - | - | |
| Joseph Peters | M | - |
University of Iowa
| 4 years |
| Mirrin B. McDougald | M | - |
University of Iowa
| 4 years |
| Emily A. Einwalter | F | - |
University of Iowa
| 4 years |
| Philip Goodin | M | - |
University of Iowa
| 1 years |
| Eric Hansotia | M | 55 |
University of Iowa
| 2 years |
| Ben L. Wissink | M | 42 |
University of Iowa
| 4 years |
| Adam Claypool | M | - | - | |
| David Kasperek | M | - |
University of Iowa
| 4 years |
| Mark Christopher Rosland | M | - |
University of Iowa
| 4 years |
| Ryan Galloway | M | - |
University of Iowa
| 4 years |
| Brian C. Burns | M | - |
University of Iowa
| 4 years |
| Matt Brackmann | M | - |
University of Iowa
| 4 years |
| Benjamin M. Anderson | M | - |
University of Iowa
| 4 years |
| Paul Galloway | M | - |
University of Iowa
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 98 | 98.00% |
| Denmark | 2 | 2.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Travis Mickle
- Personal Network
